Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CGEM
CGEM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CGEM News
Growth Prospects for the EGFR-NSCLC Market Analyzed
4d ago
Newsfilter
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients
Dec 08 2025
Globenewswire
Cullinan Therapeutics' CLN-049 Shows 31% Complete Response Rate in R/R AML Patients
Dec 08 2025
Newsfilter
Cullinan Secures FDA Fast Track Designation for CLN-049 in Relapsed/Refractory AML
Dec 01 2025
NASDAQ.COM
Cullinan Receives FDA Fast Track Designation for CLN-049 in AML Treatment
Dec 01 2025
Newsfilter
Cullinan Therapeutics Receives Fast Track Designation for CLN-049
Dec 01 2025
NASDAQ.COM
Major Stocks Including Alibaba, Oscar Health, Ondas Holdings, Lumentum, and Tesla Rise on Monday
Nov 24 2025
Benzinga
LexinFintech Shares Surge Over 15%; Check Out 20 Stocks Making Moves in Premarket Trading
Nov 24 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Cullinan Therapeutics, Increases Price Target to $26
Nov 20 2025
Benzinga
Seven Tech Stocks Experience Significant Insider Selling Despite Price Increases
Oct 28 2025
MarketWatch
Taiho Oncology and Cullinan Therapeutics Showcase Zipalertinib Data for NSCLC Patients with EGFR Mutations and Active Brain Metastases at ESMO Congress 2025
Oct 12 2025
Newsfilter
Cullinan Therapeutics to Join Fireside Chat at Stifel's 2025 Virtual Forum on Immunology and Inflammation
Sep 12 2025
Newsfilter
HC Wainwright & Co. Affirms Buy Rating for Cullinan Therapeutics, Keeps $24 Price Target Intact
Sep 12 2025
Benzinga
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Sep 09 2025
PRnewswire
Three Biotech Stocks Rated 'Strong Buy' by Analysts with Potential Upside Exceeding 300%
Sep 05 2025
TipRanks
Show More News
